Gary Aston-Jones
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Gary Aston-Jones has a total of 144 co-authors. Here are the top co-authors by number of shared publications:
- Morgan H. James
Department of Psychiatry, Robert Wood Johnson Medical School, Rutgers University, Piscataway, USA
25 shared publications - Caroline B. Pantazis
Center for Alzheimer’s and Related Dementias (CARD), National Institute on Aging and National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD 20814, USA
9 shared publications - Brandon Stephen Bentzley
Department of Psychiatry and Behavioral Sciences, Stanford University, Stanford, California
7 shared publications Jennifer E. Fragale
Brain Health Institute, Rutgers Biomedical Health Sciences, Rutgers University, Piscataway, New Jersey, USA
6 shared publications- Stephen Vincent Mahler
Department of Neurobiology & Behavior, University of California, Irvine. 1203 McGaugh Hall, Irvine, CA 92697, USA
5 shared publications - Amy Stave Kohtz
Department of Psychiatry and Human Behavior, University of Mississippi Medical Center
4 shared publications
Latest Publications
- Open Access
- 13 October 2025
- Published by Springer Nature in Research Square
Augmented orexin/hypocretin signaling underlies negative affect during acute oxycodone abstinence in rats.
Opioid use disorder (OUD) is associated with a withdrawal-induced negative affective state, which contributes to uncontrolled use via negative reinforcement. The orexin (hypocretin) system is implicated in physical opioid withdrawal. We sought to test whether the orexin system is involved in negative affect during withdrawal from chronic prescription opioid exposure. Rats received non-contingent saline or oxycodone over 21d and were assessed for behaviors indicative of negative affect. We tested whether chronic oxycodone was associated with changes in orexin cell number or activity. We used chemogenetics in transgenic rats to modulate the activity of orexin neurons to determine their functional role in development of negative affect. Chronic oxycodone induced a negative affective state during acute abstinence that included relative weight loss, allodynia, and anhedonia-, anxiety, and despair-like behaviors. Oxycodone treatment was associated with an increase in the number and activity of orexin-immunoreactive neurons; the magnitude of negative affect severity directly correlated with the number of activated orexin neurons during acute abstinence. Chronic chemogenetic inhibition of orexin neurons concomitant with oxycodone exposure attenuated development of affective symptoms. Our data support a role for the orexin system in opioid withdrawal-associated negative affect and highlight this system as a potential treatment target for OUD.
- 13 October 2025
- Published by Springer Nature in Research Square
Open AccessAugmented orexin/hypocretin signaling underlies negative affect during acute oxycodone abstinence in rats.
Opioid use disorder (OUD) is associated with a withdrawal-induced negative affective state, which contributes to uncontrolled use via negative reinforcement. The orexin (hypocretin) system is implicated in physical opioid withdrawal. We sought to test whether the orexin system is involved in negative affect during withdrawal from chronic prescription opioid exposure. Rats received non-contingent saline or oxycodone over 21d and were assessed for behaviors indicative of negative affect. We tested whether chronic oxycodone was associated with changes in orexin cell number or activity. We used chemogenetics in transgenic rats to modulate the activity of orexin neurons to determine their functional role in development of negative affect. Chronic oxycodone induced a negative affective state during acute abstinence that included relative weight loss, allodynia, and anhedonia-, anxiety, and despair-like behaviors. Oxycodone treatment was associated with an increase in the number and activity of orexin-immunoreactive neurons; the magnitude of negative affect severity directly correlated with the number of activated orexin neurons during acute abstinence. Chronic chemogenetic inhibition of orexin neurons concomitant with oxycodone exposure attenuated development of affective symptoms. Our data support a role for the orexin system in opioid withdrawal-associated negative affect and highlight this system as a potential treatment target for OUD.
- Open Access
- 10 September 2025
- Published by Edinburgh University Library in IUPHAR/BPS Guide to Pharmacology CITE
- Vol. 2025 (3)
Orexin receptors in GtoPdb v.2025.3
Orexin receptors (nomenclature as agreed by the NC-IUPHAR Subcommittee on Orexin receptors [79]) are activated by the endogenous polypeptides orexin-A and orexin-B (also known as hypocretin-1 and -2; 33 and 28 aa) derived from a common precursor, prepro-orexin or orexin precursor, by proteolytic cleavage and some typical peptide modifications [120, 79]. Orexin signaling has been associated with regulation of sleep and wakefulness, reward and addiction, appetite and feeding, pain gating, stress response, anxiety and depression. Currently the orexin receptor ligands in clinical use are the dual orexin receptor antagonists suvorexant, lemborexant and daridorexant, which are used as hypnotics, and several dual, as well as OX1- and OX2-selective antagonists are under development for different indications. Multiple orexin agonists are in development for the treatment of narcolepsy and other sleep disorders. Orexin receptor 3D structures have been solved [150, 148, 55, 130, 47, 113, 7, 149].
- 10 September 2025
- Published by Edinburgh University Library in IUPHAR/BPS Guide to Pharmacology CITE
- Vol. 2025 (3)
Open AccessOrexin receptors in GtoPdb v.2025.3
Orexin receptors (nomenclature as agreed by the NC-IUPHAR Subcommittee on Orexin receptors [79]) are activated by the endogenous polypeptides orexin-A and orexin-B (also known as hypocretin-1 and -2; 33 and 28 aa) derived from a common precursor, prepro-orexin or orexin precursor, by proteolytic cleavage and some typical peptide modifications [120, 79]. Orexin signaling has been associated with regulation of sleep and wakefulness, reward and addiction, appetite and feeding, pain gating, stress response, anxiety and depression. Currently the orexin receptor ligands in clinical use are the dual orexin receptor antagonists suvorexant, lemborexant and daridorexant, which are used as hypnotics, and several dual, as well as OX1- and OX2-selective antagonists are under development for different indications. Multiple orexin agonists are in development for the treatment of narcolepsy and other sleep disorders. Orexin receptor 3D structures have been solved [150, 148, 55, 130, 47, 113, 7, 149].
- Open Access
- 15 May 2025
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 122 (20)
A founding father of neuroscience: Floyd E. Bloom, 1936–2025
Floyd E. Bloom, M.D. was a prominent leader and spokesperson for the neuroscience and broader scientific communities; sadly, Floyd passed away on January 8, 2025. His scientific contributions were focused on multidisciplinary characterizations of transmitter-specific neural pathways in the brain. An innovative neuroanatomist and neurophysiologist, he spearheaded the development of new techniques and multidisciplinary paradigms for demonstrating the functions of neurotransmitters at the circuit, cellular, and subcellular levels. His work was especially important for mapping monoaminergic and peptidergic pathways and describing their physiologic and behavioral roles. He played a seminal role in developing the field of modern neuropharmacology at all levels, from the molecular to the behavioral.
- 15 May 2025
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 122 (20)
Open AccessA founding father of neuroscience: Floyd E. Bloom, 1936–2025
Floyd E. Bloom, M.D. was a prominent leader and spokesperson for the neuroscience and broader scientific communities; sadly, Floyd passed away on January 8, 2025. His scientific contributions were focused on multidisciplinary characterizations of transmitter-specific neural pathways in the brain. An innovative neuroanatomist and neurophysiologist, he spearheaded the development of new techniques and multidisciplinary paradigms for demonstrating the functions of neurotransmitters at the circuit, cellular, and subcellular levels. His work was especially important for mapping monoaminergic and peptidergic pathways and describing their physiologic and behavioral roles. He played a seminal role in developing the field of modern neuropharmacology at all levels, from the molecular to the behavioral.
- Open Access
- 5 March 2025
- Published by Springer Nature in Neuropsychopharmacology
- Vol. 50 (6) , 1017-1018
IN MEMORIAM: Floyd E. Bloom, M.D
- 5 March 2025
- Published by Springer Nature in Neuropsychopharmacology
- Vol. 50 (6) , 1017-1018
Open AccessIN MEMORIAM: Floyd E. Bloom, M.D
- Open Access
- 25 February 2025
- Published by Springer Nature in Nature Neuroscience
- Vol. 28 (4) , 707-708
Floyd E. Bloom (1936–2025)
- 25 February 2025
- Published by Springer Nature in Nature Neuroscience
- Vol. 28 (4) , 707-708
Open AccessFloyd E. Bloom (1936–2025)
- Open Access
- 9 October 2024
- Published by Elsevier in Addiction Neuroscience
- Vol. 13
Fentanyl demand and seeking in female rats: Role of the orexin system and estrous cycle
- 9 October 2024
- Published by Elsevier in Addiction Neuroscience
- Vol. 13
Open AccessFentanyl demand and seeking in female rats: Role of the orexin system and estrous cycle
- Open Access
- 1 July 2024
- Published by American Physiological Society in Journal of Neurophysiology
- Vol. 132 (1) , 226-239
In search of the locus coeruleus: guidelines for identifying anatomical boundaries and electrophysiological properties of the blue spot in mice, fish, finches, and beyond
Our understanding of human brain function can be greatly aided by studying analogous brain structures in other organisms. One brain structure with neurochemical and anatomical homology throughout vertebrate species is the locus coeruleus (LC), a small collection of norepinephrine (NE)-containing neurons in the brainstem that project throughout the central nervous system. The LC is involved in nearly every aspect of brain function, including arousal and learning, which has been extensively examined in rats and nonhuman primates using single-unit recordings. Recent work has expanded into putative LC single-unit electrophysiological recordings in a nonmodel species, the zebra finch. Given the importance of correctly identifying analogous structures as research efforts expand to other vertebrates, we suggest adoption of consensus anatomical and electrophysiological guidelines for identifying LC neurons across species when evaluating brainstem single-unit spiking or calcium imaging. Such consensus criteria will allow for confident cross-species understanding of the roles of the LC in brain function and behavior.
- 1 July 2024
- Published by American Physiological Society in Journal of Neurophysiology
- Vol. 132 (1) , 226-239
Open AccessIn search of the locus coeruleus: guidelines for identifying anatomical boundaries and electrophysiological properties of the blue spot in mice, fish, finches, and beyond
Our understanding of human brain function can be greatly aided by studying analogous brain structures in other organisms. One brain structure with neurochemical and anatomical homology throughout vertebrate species is the locus coeruleus (LC), a small collection of norepinephrine (NE)-containing neurons in the brainstem that project throughout the central nervous system. The LC is involved in nearly every aspect of brain function, including arousal and learning, which has been extensively examined in rats and nonhuman primates using single-unit recordings. Recent work has expanded into putative LC single-unit electrophysiological recordings in a nonmodel species, the zebra finch. Given the importance of correctly identifying analogous structures as research efforts expand to other vertebrates, we suggest adoption of consensus anatomical and electrophysiological guidelines for identifying LC neurons across species when evaluating brainstem single-unit spiking or calcium imaging. Such consensus criteria will allow for confident cross-species understanding of the roles of the LC in brain function and behavior.
- Open Access
- 21 March 2024
- Published by Society for Neuroscience in Journal of Neuroscience
- Vol. 44 (17)
Serotonin signaling in hippocampus during initial cocaine abstinence drives persistent drug seeking
The initiation of abstinence after chronic drug self-administration is a stressful event. Cocaine-seeking behavior on the first day of the absence of expected drug (extinction day 1, ED1) is reduced by blocking 5-HT signaling in dorsal hippocampus CA1 (CA1) in both male and female rats. We hypothesized that the experience of ED1 can substantially influence later relapse behavior, and that dorsal raphe serotonin (DR 5-HT) input to CA1 may be involved. We inhibited 5-HT1A/1B receptors (WAY100,635 plus GR127935), or DR input (chemogenetics), in CA1 on ED1 to test the role of this pathway on cocaine-seeking persistence 2wk later. We also inhibited 5-HT1A or 5-HT1B receptors in CA1 during conditioned place preference (CPP) for cocaine, to examine mechanisms involved in persistent effects of ED1 manipulations. Inhibition of DR inputs, or 5-HT1A/1B signaling, in CA1 decreased drug-seeking on ED1 and decreased cocaine-seeking 2wk later revealing that 5-HT signaling in CA1 during ED1 contributes to persistent drug-seeking during abstinence. In addition, 5-HT1B antagonism alone transiently decreased drug-associated memory performance when given prior to a conditioned place preference (CPP) test, whereas similar antagonism of 5-HT1A alone had no such effect but blocked CPP retrieval on a test 24h later. These CPP findings are consistent with prior work showing that DR inputs to CA1 augments recall of the drug-associated context and drug-seeking via 5-HT1B receptors and prevents consolidation of the updated non-drug context via 5-HT1A receptors. Thus, treatments that modulate 5-HT dependent memory mechanisms in CA1 during initial abstinence may facilitate later maintenance of abstinence. Significance Statement One of the most complex issues associated with substance use disorder (SUD) treatment is the development of strategies that assist in the initiation and maintenance of abstinence from drug taking. Herein, we show that the persistent propensity for cocaine-seeking during abstinence can be attenuated by 5-HT1A/5-HT1B receptor antagonists, or by inhibition of dorsal raphe signaling to dorsal hippocampus. Our results provide insight towards potential clinical applications for treatment of addiction in human populations.
- 21 March 2024
- Published by Society for Neuroscience in Journal of Neuroscience
- Vol. 44 (17)
Open AccessSerotonin signaling in hippocampus during initial cocaine abstinence drives persistent drug seeking
The initiation of abstinence after chronic drug self-administration is a stressful event. Cocaine-seeking behavior on the first day of the absence of expected drug (extinction day 1, ED1) is reduced by blocking 5-HT signaling in dorsal hippocampus CA1 (CA1) in both male and female rats. We hypothesized that the experience of ED1 can substantially influence later relapse behavior, and that dorsal raphe serotonin (DR 5-HT) input to CA1 may be involved. We inhibited 5-HT1A/1B receptors (WAY100,635 plus GR127935), or DR input (chemogenetics), in CA1 on ED1 to test the role of this pathway on cocaine-seeking persistence 2wk later. We also inhibited 5-HT1A or 5-HT1B receptors in CA1 during conditioned place preference (CPP) for cocaine, to examine mechanisms involved in persistent effects of ED1 manipulations. Inhibition of DR inputs, or 5-HT1A/1B signaling, in CA1 decreased drug-seeking on ED1 and decreased cocaine-seeking 2wk later revealing that 5-HT signaling in CA1 during ED1 contributes to persistent drug-seeking during abstinence. In addition, 5-HT1B antagonism alone transiently decreased drug-associated memory performance when given prior to a conditioned place preference (CPP) test, whereas similar antagonism of 5-HT1A alone had no such effect but blocked CPP retrieval on a test 24h later. These CPP findings are consistent with prior work showing that DR inputs to CA1 augments recall of the drug-associated context and drug-seeking via 5-HT1B receptors and prevents consolidation of the updated non-drug context via 5-HT1A receptors. Thus, treatments that modulate 5-HT dependent memory mechanisms in CA1 during initial abstinence may facilitate later maintenance of abstinence. Significance Statement One of the most complex issues associated with substance use disorder (SUD) treatment is the development of strategies that assist in the initiation and maintenance of abstinence from drug taking. Herein, we show that the persistent propensity for cocaine-seeking during abstinence can be attenuated by 5-HT1A/5-HT1B receptor antagonists, or by inhibition of dorsal raphe signaling to dorsal hippocampus. Our results provide insight towards potential clinical applications for treatment of addiction in human populations.
- Open Access
- 26 April 2023
- Published by Edinburgh University Library in IUPHAR/BPS Guide to Pharmacology CITE
- Vol. 2023 (1)
Orexin receptors in GtoPdb v.2023.1
Orexin receptors (nomenclature as agreed by the NC-IUPHAR Subcommittee on Orexin receptors [43]) are activated by the endogenous polypeptides orexin-A and orexin-B (also known as hypocretin-1 and -2; 33 and 28 aa) derived from a common precursor, preproorexin or orexin precursor, by proteolytic cleavage and some typical peptide modifications [117]. Orexin signaling has been associated with regulation of sleep and wakefulness, reward and addiction, appetite and feeding, pain gating, stress response, anxiety and depression. Currently the orexin receptor ligands in clinical use are the dual orexin receptor antagonists suvorexant and lemborexant and daridorexant, which are used as hypnotics, and several dual and OX2-selective antagonists are under development. Multiple orexin agonists are in development for the treatment of narcolepsy and other sleep disorders. Orexin receptor 3D structures have been solved [146, 144, 55, 126, 47, 109, 7, 145].
- 26 April 2023
- Published by Edinburgh University Library in IUPHAR/BPS Guide to Pharmacology CITE
- Vol. 2023 (1)
Open AccessOrexin receptors in GtoPdb v.2023.1
Orexin receptors (nomenclature as agreed by the NC-IUPHAR Subcommittee on Orexin receptors [43]) are activated by the endogenous polypeptides orexin-A and orexin-B (also known as hypocretin-1 and -2; 33 and 28 aa) derived from a common precursor, preproorexin or orexin precursor, by proteolytic cleavage and some typical peptide modifications [117]. Orexin signaling has been associated with regulation of sleep and wakefulness, reward and addiction, appetite and feeding, pain gating, stress response, anxiety and depression. Currently the orexin receptor ligands in clinical use are the dual orexin receptor antagonists suvorexant and lemborexant and daridorexant, which are used as hypnotics, and several dual and OX2-selective antagonists are under development. Multiple orexin agonists are in development for the treatment of narcolepsy and other sleep disorders. Orexin receptor 3D structures have been solved [146, 144, 55, 126, 47, 109, 7, 145].
- 31 October 2022
- Published by Elsevier in Biological Psychiatry
- Vol. 92 (11) , A3-A4
Table of Contents